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Abstract 
After many efforts to improve and standardize assays for detecting immune 
biomarkers in type 1 diabetes (T1D), methods to identify and monitor such correlates 
of insulitis are coming of age. The ultimate goal is to use these correlates to predict 
disease progression before onset and regression following therapeutic intervention, 
which would allow performing smaller and shorter pilot clinical trials with earlier 
endpoints than those offered by preserved β-cell function or improved glycemic 
control. Here, too, progress has been made. With the emerging insight that T1D 
represents a heterogeneous disease, the next challenge is to define patient 
subpopulations that qualify for personalized medicine or that should be enrolled for 
immune intervention, to maximize clinical benefit and decrease collateral damage by 
ineffective or even adverse immune therapeutics. This review discusses the current 
state of the art, setting the stage for future efforts to monitor disease heterogeneity, 
progression and therapeutic intervention in T1D. 
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1. Introduction 
Type 1 diabetes (T1D) represents a prototypic tissue-specific autoimmune disease 
[1]. Indeed, progress in unraveling the immune components involved in the 
pathogenesis of T1D has been spectacular and often more rewarding than for other 
autoimmune diseases. Several islet antigens (Ags) have been identified with 
compelling associations with the β-cell destruction process, including (pre)proinsulin 
[(pre)PI], glutamic acid decarboxylase (GAD)65, insulinoma-associated protein 2 (IA-
2), islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) and 
zinc transporter (ZnT)8 [2-4]. Additional candidate target molecules expressed by β 
cells have been revealed and studied, such as chromogranin A, (prepro) islet amyloid 
polypeptide (ppIAPP), peripherin and an ill-defined 38 kDa protein in insulin secretory 
granules, but their role in and association with clinical T1D remains unclear or 
controversial [5]. The immunology of diabetes community has been blessed with this 
large series of T-cell and/or autoantibody (autoAb) targets that can be employed in 
monitoring the islet autoreactivity of T1D [6]. Islet autoAbs against many of these Ags 
have proven particularly useful for T1D prediction, but less so for following disease 
activity and progression after T1D onset or during therapeutic intervention (so called 
“immune staging”) [7]. This notion is putting a substantial burden on the options to 
monitor changes in disease activity. It implies that we may have to resort to using 
cellular autoimmunity to this end, with all the challenges involved in terms of 
technologies and targets. 
New access to the pancreatic lesions of T1D patients through the establishment of an 
international consortium collecting, distributing and characterizing tissues of diabetic 
donors (www.jdrfnpod.org) has led spectacular new insights into the immune 
processes involved in the selective destruction of insulin-producing β cells in 
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pancreatic islets [8]. Seminal recent lessons learned through these studies include 
additional proofs of the autoimmune nature of T1D, the demonstration of islet-specific 
CD8+ T cells in destructive insulitic lesions, the unexpectedly low frequencies of islet-
infiltrating CD4+ T cells, the apparent lack of CD4+CD25+FoxP3+ T regulatory cells 
(Tregs) in insulitis, the profound difference in immunopathology between men and 
mice, an overwhelming heterogeneity in the pathologic lesions and patient 
population, and the demonstration of focal disease activity much akin to what 
observed in other tissue-specific autoimmune diseases such as vitiligo [9]. 
Collectively, these insights have set the stage for new therapeutic strategies that may 
also prove effective in protecting β cells long after T1D clinical onset. Many of these 
strategies are currently assessed for clinical efficacy to prevent, stop of reverse 
disease. Some recent-onset T1D patients have already achieved a lasting remission 
from insulin dependency for up to seven years, showing proof of principle that T1D 
may be cured, at least in some patients and at least for a number of years [10]. Yet, 
there is an urgent need for definition of endpoints and biomarkers of immunological 
and clinical efficacy to guide therapeutic interventions in T1D. The immune system 
holds important clues to provide immune correlates of safety and clinical efficacy, 
both for selecting the appropriate patients for a given therapy and to monitor whether 
the intervention can preserve β-cell function. 
  
2. T1D: a T-cell-mediated autoimmune disease 
T1D is an autoimmune disease in which CD4+ and CD8+ T cells infiltrate the islets of 
Langerhans, resulting in β-cell destruction. Although the precise etiologic factors 
remain barely elusive, an extensive body of data in animal models and more limited 
studies in man indicate that, contrary to autoAbs [11], CD4+ and CD8+ T cells reactive 
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with islet Ags have a key role in the process of β-cell destruction. The lines of 
evidence gathered in mouse models have been extensively reviewed, and the notion 
of a central pathogenic role for T cells in the diabetes of non-obese diabetic (NOD) 
mouse models is widely accepted. Focusing on data from human studies, one first 
line of evidence comes from histological analyses of pancreata from newly diagnosed 
T1D patients, showing abundant T cells, mostly CD8+, present in the islet 
inflammatory infiltrates (“insulitis”). In situ HLA Class I tetramer staining analyses 
have pinpointed the specificity of these infiltrating CD8+ T cells, proving that they are 
indeed islet-reactive [8]. 
Second, some immunosuppressive drugs, including those specifically directed 
against T cells, confer some delay in T1D progression. For example, therapy with 
non-activating humanized monoclonal antibodies against the T-cell surface molecule 
CD3 at T1D onset suggests some β-cell preservation, although the doses needed to 
achieve such effect raised safety concerns [12, 13]. 
Third, CD8+ T-cell-mediated islet autoimmunity in association with T1D onset [14-17] 
and loss of islet-graft function [18] provides evidence that the peripheral blood 
represents a “window” through which anti-islet T-cell reactivity can be followed, 
reflecting the autoimmune activity present locally in the islet infiltrates [19]. CD4+ T 
cells specific for islet Ags are also circulating in T1D patients and display a pro-
inflammatory memory phenotype [20, 21]. This is at variance with what observed in 
non-diabetic control subjects, which sometimes harbour islet-reactive T cells 
displaying a putative regulatory phenotype characterized by IL-10 production. Indeed, 
T1D patients harbouring CD4+ T cells that produce IL-10 in response to islet 
epitopes developed clinical T1D on average 7 years later than those not producing 
IL-10 [20]. Similar observations have been reported for islet-reactive CD8+ T cells 
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[22]. These seminal reports invite the hypothesis that IL-10 induction by islet Ag-
specific tolerogenic vaccination may halt disease progression and preserve β-cell 
function. 
Apart from these examples of studies documenting an association between T-cell 
activity and β-cell destruction, gathering direct evidence for a cause-effect 
relationship has been more daunting. Such evidence has been provided in vitro, 
documenting that prePI-reactive CD8+ T-cell clones are capable of destroying human 
islets [23, 24]. Expanding these observations, T1D patient derived autoreactive CD4+ 
T-cell clones injected into NOD.scid mice along with HLA-matched human Ag-
presenting cells migrated to the islets, resembling early peri-islet insulitis [25]. 
Similarly, NOD.2mnull.HHD transgenic mice carrying a human HLA-A2 transgene 
and thus HLA-A2-restricted CD8+ T cells documented that CD8+ T cells isolated 
from their islets are able to lyse human HLA-A2+ islets [26]. Patient-derived CD8+ T 
cell clones with this same islet specificity and injected into NOD.2mnull.HHD mice 
lyse human transplanted target cells and home to the endogenous islets [27], 
causing insulitic lesions resembling those in new onset T1D patients [8]. Some of the 
epitopes targeted by these murine diabetogenic T-cell clones are identical to that of 
human CD8+ T-cell clones [15, 28]. Similar observations have been reported for 
GAD-reactive CD4+ T cells, which were able to destroy β cells when co-transplanted 
with human islets into immunodeficient mice [29]. Although this was not the case for 
control-reactive CD4+ T cells, the use of HLA-mismatched human islets complicates 
interpretation.  
Taken together, these data lend support for a central pathogenic role of islet-reactive 
T cells in T1D autoimmunity. 
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3. Endpoints in immune intervention trials: metabolic and immune biomarkers  
To put into context the endpoints analyzed in T1D intervention trials, the clinical stage 
at which most of these trials are performed should be kept in mind. While in the NOD 
mouse models, which is commonly used to preclinically evaluate the efficacy of 
immune therapeutics, treatment is usually started as early as possible, at a time 
when the autoimmune progression is still lagging behind, this is not feasible in 
patients. Indeed, autoAbs are the earlier available biomarkers of T1D risk. While 
extremely useful, they also provide proof that the autoimmune process is already 
floridly active. Moreover, the earliest detection of one single autoAb (typically 
targeting insulin in children) does not mark a risk considered high enough to justify 
immune intervention. Indeed, only ~10% of those individuals who are single autoAb+ 
progress to T1D during the following 5 years [30]. Individuals who develop additional 
autoAb reactivities during follow up significantly increase their risk of developing T1D 
(~80% at 5 years) [30], reflecting their more advanced stage of autoimmune 
progression and Ag spreading. However, also in this case the risk-benefit balance 
poses delicate ethical issues in T1D. This is because, contrary to more deadly 
diseases, the prognosis of T1D once disease is diagnosed is relatively benign for 
several decades and life expectancy approaches that of healthy subjects when 
glycemic control is satisfactory. If we add that most at-risk individuals have high yet 
not ineluctable odds of progressing to T1D, it is clear that the “treat/not treat” 
equation is difficult to solve, especially when using immune therapeutics with 
unknown long-term benefits and harms. It is for all these reasons that most 
intervention trials are performed soon after and not before T1D onset. At this time, 
not only β-cell autoimmunity is far advanced, but also a consistent fraction of the β-
cell mass has already been destroyed. 
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The exact fraction of remaining β cells is a matter of debate and is highly variable, 
ranging from as low as 15% in children to as high as 60% in adults [31]. Moreover, 
although it is increasingly suggested that this β-cell mass may regenerate to some 
extent, definite evidence is lacking. It appears that even the most effective immune 
therapy capable of completely halting autoimmunity may only rescue a limited β-cell 
function. The challenge embraced by immune intervention trials performed at T1D 
onset is therefore a daunting one. 
While clinical endpoints such as HbA1c values and insulin needs are part of trial 
follow-ups, they are exposed to a number of confounding variables such as lifestyle, 
insulin sensitivity and practices of different diabetologists which make them of limited 
reliability. Hence, the most widely used endpoints are metabolic biomarkers which 
should more reliably reflect the degree of β-cell preservation. This is assessed by 
measuring C-peptide secretion (which is equimolar to insulin secretion) following β-
cell stimulation with a standardized meal (so called “mixed meal tolerance test”) [32]. 
While these endpoints provide the most accurate estimation of clinical efficacy to 
date, they have important limitations. First, given the advanced stage of islet damage, 
the modifications to be expected in these parameters are limited. Said otherwise, we 
may conclude that an intervention is ineffective while it could have been beneficial if 
administered at an earlier time point, i.e. before T1D onset. Second, limited metabolic 
changes also mean higher patient numbers that need to be enrolled to provide 
sufficient statistical power to conclude for a clinical benefit. Third, metabolic 
parameters can only be assessed at the end of the trial, thus taking several months 
or years. Fourth, recent awareness has risen suggesting that β-cell function need not 
equal β-cell mass. Indeed, the persistence of β cells and insulin production as well as 
inflammatory insulitic lesions many years after clinical T1D onset have been reported 
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[8]. Moreover, there is an apparent discordance between β-cell mass and function, 
which may reflect some degree of β-cell quiescence reminiscent of “stunned” 
myocardiocytes in ischemic heart disease. These elements make it more challenging 
to sensitively measure residual β-cell capacity late after T1D onset. This further 
invites the use of other endpoints such as immune correlates of disease progression 
and therapeutic intervention [33]. Such new endpoints may decrease time required to 
assess therapeutic efficacy and allow for smaller numbers of patients per treatment 
arm.   
There are therefore several good reasons to include immune biomarkers in the 
follow-up of immune intervention trials [7]. First, these biomarkers can change quite 
rapidly, already some weeks or months after treatment, thus providing earlier 
endpoints than those delivered by metabolic measures. Second, immune biomarkers 
provide key information about immunological efficacy, i.e. to assess whether the type 
of immune deviation that was aimed has been achieved. This information is even 
more critical when the clinical outcome is not improved, as it allows to sort out 
between two explanations: is this due to lack of immune efficacy? Or rather, is 
immune efficacy obtained yet insufficient to provide significant clinical benefit? Third, 
immune biomarkers may provide indications on how to perform better in subsequent 
trials, by identifying immune signatures associated with clinical benefits. Such 
immune signatures may be present before treatment, allowing to enroll only those 
patients with the best chances to respond; or during intervention, informing decisions 
on whether to continue treating or not.  
 
4. Why using T cells rather than autoAbs as immune biomarkers for trial 
monitoring? 
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AutoAbs remain the mainstay for classifying diabetes cases as autoimmune-
mediated (type 1) and for stratifying risk in first-degree relatives. Can their 
modifications also be used as immune biomarkers in trial follow-ups? This was 
performed for instance in an anti-CD3 phase II trial in new-onset T1D patients [34]. 
Despite evidence for a better preservation of residual insulin secretion in anti-CD3- 
vs. placebo-treated patients, there was no significant change in autoAb titers. Lack of 
modifications in autoAb titers could simply reflect the fact that T cells but not B cells 
are targeted by anti-CD3 treatment. Indeed, the recent T1D TrialNet trial employing 
the anti-CD20 Ab rituximab [35], which instead targets Ag-presenting B cells, 
documented disappearance of anti-insulin autoAbs (IAAs) in 40% of rituximab-treated 
patients vs. 0% of placebo-treated ones, both IAA+ before treatment [36]. 
Ag vaccination trials have also invited to analyze changes in humoral immunity not in 
terms of preexisting autoAb responses, but rather of Ab developing against the 
exogenous vaccinal Ag. This has been documented in the GAD-alum vaccination 
trials, where subcutaneous administration was followed by a steep rise in anti-GAD 
Abs peaking at 3 months [37], which subsequently persisted at lower titers up to the 
latest available 4-year follow-up [38]. Nonetheless, whether this rise should be 
regarded as a biomarker suggestive of a favorable immune outcome is unclear. On 
one side, Ab responses are frequently associated with a T helper 2 (Th2) deviation of 
T-cell responses, which represent a potentially desirable effect shifting away from 
more pathogenic Th1 responses. On the other hand, Ag-specific Abs can also favor 
activation of cognate T cells, at least in vitro [39]. Thus, also in the case of Ag 
vaccination trials, it seems important to interpret these changes in Ab titers to 
exogenously administered Ags in light of the associated changes in the 
corresponding T-cell responses. This was performed in the intranasal insulin 
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prevention trial, where at-risk individuals treated with the active compound displayed 
a rise in Abs against exogenous insulin along with a concomitant decline in insulin-
stimulated proliferative T-cell responses [40]. 
These results argue against the (exclusive) use of autoAbs as immune biomarkers 
for trial monitoring. First, T1D is a T-cell-mediated autoimmune disease and most 
therapeutic strategies target this lymphocyte population. Second, autoAb secretion is 
provided by long-lived plasma cells, while memory B cells can further differentiate 
into plasma cells in the case of persistent or recurrent Ag stimulation. Such dynamics 
are largely T-cell-independent once the primary immune response has subsided, 
making changes in autoAb titers slow in kinetics and poorly influenced by 
concomitant changes in the corresponding Ag-specific T-cell compartments. A third 
reason is offered by the more rapid modifications of T-cell responses compared to 
(auto)Ab-producing B cells. Evidence for such different kinetics was gathered in new-
onset T1D patients followed for both autoAb and T-cell responses at diagnosis and 
after a median follow-up of 11 months. While GAD and IA-2 autoAb titers were 
unchanged in 75% of cases, the fraction of patients displaying IFN-γ-secreting T-cell 
responses specific for prePI and/or GAD epitopes decreased from ~65% to 20% [28]. 
In this “spontaneous” setting, i.e. in the absence of immune intervention, this 
modification in T-cell responses may be due either to decreased Ag stimulation owing 
to a decline in the β-cell mass; or to a tolerogenic effect of insulin therapy [41, 42]. 
 
5. Measuring T-cell responses in T1D 
In front of the advantages of monitoring T-cell rather than autoAb responses, there 
are also some drawbacks, namely that T-cell assays are technically more demanding 
[43-46]. These assays employ live peripheral blood mononuclear cells (PBMCs), 
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which should be prepared and stored following procedures not routinely implemented 
in clinical laboratories. Following the successful efforts of the Diabetes Antibody 
Standardization Program (DASP) over the last two decades, the T-Cell Workshop 
initiative of the Immunology of Diabetes Society is providing guidelines on how to 
handle these biological samples [44]. The other key mission of the T-Cell Workshop 
is to launch multicentre initiatives to independently validate and standardize T-cell 
assays which have performed well in single-center studies [47].   
Another obvious challenge is that T-cell assays are better poised to detect relevant 
biomarkers when used to analyze responses against β-cell Ags rather than 
polyclonal T-cell responses as a whole. Arguably, analyzing T-cell responses 
independently of their Ag specificity is like analyzing titers of the whole Ab repertoire 
of a given individual. It is conceivable that treatments that are deemed to be non-
immunosuppressive or even Ag-specific will induce changes that remain 
undetectable at a polyclonal level. If polyclonal changes are detectable, they may 
even suggest that the tolerogenic effect is not selective enough and that a 
generalized immunosuppression is instead achieved. There is therefore a pressing 
need for robust assays capable of measuring the physical disappearance or 
functional silencing of islet-reactive T cells, or the appearance/activation of Treg 
populations. This need is most compelling in the setting of immune intervention trials, 
to provide readouts for the T cells that are targeted by most therapies. To perform T-
cell assays of this kind, it is therefore essential to continue mapping the molecular 
targets (Ags and epitopes thereof) recognized by such T cells.              
 
6. Applications of immune biomarkers for trial monitoring 
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Monitoring of clinical trials by means of immune biomarkers can address a number of 
questions posed by immune interventions (Figure 1). Such questions fall into three 
main categories: therapeutic safety, i.e. are we causing unwanted immune activation 
or, conversely, are we inducing generalized immune suppression?; immunological 
efficacy, i.e. did we achieve the immune deviation that we set out for?; and, 
ultimately, therapeutic efficacy, i.e. is the immunological change achieved associated 
with clinical efficacy? 
  
6.1. Immune biomarkers of therapeutic safety 
Negative clinical outcomes of an immune therapeutic intervention can sometimes be 
revealed by accelerated disease progression, as defined by worsening glycemic 
control, increased insulin needs or decreased β-cell function. While disease 
acceleration has been observed in immunotherapy trials performed in other 
autoimmune diseases such as multiple sclerosis [48], this has fortunately not been 
the case for T1D. The same is true for acute development of clinical complications, 
with the only partial exception of EBV reactivation during the European “high-dose” 
anti-CD3 phase II trial [34]. Several mainstream immune and viral biomarkers are 
routinely used to monitor and pre-empt such adverse events. Unwanted type I 
immune activation can also be promptly revealed by allergic or skin reactions, 
anaphylaxis or eosinophilia. 
One more difficult question to address is whether the immune intervention is truly 
inducing a state of (islet-specific) immune tolerance or rather one of generalized 
immune suppression, be it in the absence of or despite obvious laboratory 
abnormalities such as lymphopenia. Given the lack of suitable parameters to gauge 
the in vivo responsiveness of the immune system [49], one way to address this is to 
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vaccinate patients with an irrelevant neo-Ag during treatment follow-up and to 
subsequently assess the efficacy of such vaccination in terms of immune responses. 
Although only naïve responses are evaluated, such approach provides a useful proxy 
of suitable immune competence to minimize the risk of viral infections/reactivations 
and secondary tumor growth. This strategy has been applied in the TrialNet anti-
CD20 trial, where treated patients were immunized with the phiX174 neo-Ag following 
B-cell recovery and developed normal IgM titers [35]. Wider evaluation of these 
safety parameters would be desirable for T1D trials, and active research is ongoing 
to define simplified in vitro measures predictive of subsequent in vivo response to Ag 
challenges. On the same lines, in vitro preclinical studies that explore potential 
toxicities of novel therapeutics on human PBMCs (e.g. cytokine release in the 
presence or absence of the drug and of recall Ag stimuli) would be beneficial [33]. 
 
6.2. Immune biomarkers of immunological efficacy 
This is the trial monitoring application for which T-cell biomarkers can yield more 
information, especially in the context of tolerogenic Ag vaccination [50]. In terms of 
adverse reactivities, these can be defined by changes in (auto)immune responses in 
undesired directions, e.g. increased autoimmunity (autoAbs, islet specific CD4+ or 
CD8+ T-cell responses) or immune modulation skewed towards inflammation (IFN-, 
IL-17). Technologies are in place to define such adverse autoimmune responses, 
provided that these occur in the circulation or in skin reactions and at reasonably high 
intensity or frequency. Particularly in the case of Ag-specific immunotherapies, 
immune responses to the islet Ag of choice may be specifically measured in terms of 
quality and quantity, but the relatively low precursor frequencies of islet-reactive T 
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cells, in particular in the case of CD4+ T cells, may hamper their reliable, sensitive 
and robust identification.  
One study was recently reported on autoAb+ diabetic patients not requiring insulin at 
the time of diagnosis. These patients were intranasally vaccinated with insulin or 
placebo in an attempt to save residual β cells [51]. Although nasal insulin-treated 
patients eventually progressed towards insulin dependency at a rate similar to the 
placebo arm, successful induction of insulin-specific immune tolerance was 
documented both at the T-cell and Ab level [51]. Contrary to the placebo arm, 
patients treated with intranasal insulin displayed marked reductions in IFN-γ-
secreting T-cell responses to PI. This effect was Ag-specific, since it was not 
observed for the tetanus toxoid recall Ag. Once insulin therapy intiated, intranasal 
insulin-treated subjects also failed to develop anti-insulin Abs, further documenting 
that this PI-specific tolerance was operational in vivo [51]. 
Another example of immunological efficacy assessed through immune biomarkers 
comes from the Diamyd GAD-alum subcutaneous vaccination trial performed on 
new-onset T1D adolescents in Sweden [38]. Results of T-cell monitoring were 
different in this case, showing that GAD-alum, but not placebo treatment, did not 
blunt, but instead selectively boosted GAD-specific T-cell responses. Moreover, 
these T-cell responses did not shown a tolerogenic deviation towards secretion of 
Th2 or regulatory cytokines, as Th1 cytokines were equally produced. Furthermore, 
patients displaying a better clinical outcome (i.e. C-peptide decline ≤60%) were also 
characterized by GAD-induced T-cell responses more deviated towards favorable 
Th2 (IL-5, IL-13) and regulatory (IL-10) cytokine profiles. These results suggest that, 
in the case of GAD-alum vaccination, the immune modifications induced are not 
selectively driven towards the desired outcome.  
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Other recent examples of specific changes in immune responses to islet epitopes in 
Ag-specific immune responses in a favorable direction include immune modulation 
with the heat-shock protein-derived peptide DiaPep277 or PI, even though these do 
not necessarily associate with clinical benefit [52, 53]. Yet, such immunological 
changes may point to mechanisms of action and as such point to another relevant 
incentive for immune monitoring efforts in the context of intervention studies.  
 
6.3. Immune biomarkers of therapeutic clinical efficacy 
The previous examples gathered from intranasal insulin, GAD and peptide 
vaccination trials exemplify how T-cell surrogates of immunological efficacy do not 
need to be identical to those associated with clinical efficacy. In fact, it is relevant to 
learn whether a given immunotherapy achieved the desired immune modification, 
despite failure to affect T1D progression [7]. As explained before, we argue that 
immune surrogates of failed clinical efficacy are equally useful to guide data 
interpretation and to inform further trial design. However, several cases have recently 
emerged of immune biomarkers that either predict or associate with clinical benefit 
from immunotherapy. Intriguingly, immune correlates that predict clinical outcome 
may not necessarily be the same as those that follow successful immune 
intervention. For instance, an immune response manifested by IL-10 production to  
DiaPep277 before therapy correlated with preserved β-cell function (regardless of 
subsequent DiaPep277 injection), but after treatment, all treated patients elicited an 
IL-10 response to DiaPep277, regardless of whether β-cell function was preserved or 
not. Instead, loss of a proliferative T-cell response to DiaPep277 following therapy 
correlated with clinical benefit in terms of preserved β-cell function [52]. This example 
also illustrates how immune correlates may differ before and after therapy.   
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6.4. Immune correlates of remission and relapse in islet transplantation 
A perhaps easier opportunity than monitoring natural progression and therapeutic 
intervention shortly after disease onset is provided by clinical islet transplantation [54, 
55]. Even though this setting is more complicated in the sense that alloreactivity to 
the islet allograft donor and concomitant immunosuppression adds to the complexity 
determining the in vivo fate of transplanted islets, the timelines are more concrete 
and synchronized with the defined time of re-introduction of islet Ags. Indeed, several 
important lessons have already been drawn from immune monitoring efforts. These 
include the overwhelming importance of (auto)immune memory (causing recurrence 
of autoimmune β-cell destruction and loss of graft function) [56]; the definition of 
baseline immune correlates affecting and predicting clinical efficacy (such as simple 
T and B-lymphocyte counts, baseline CD4+ or CD8+ T-cell autoreactivity) [16, 57, 58] 
that may allow staging of patients with superior or inferior clinical benefits; and the 
importance of matching of islet recipients with donors, and between donors in the 
case of repeated grafting [59, 60]. 
The significance of islet autoAbs at the time of islet transplantation as adverse 
immune parameter is more controversial and depending on the particular type of 
induction therapy (daclizumab, basilixumab, thymoglobulin or alemtuzumab) and 
maintenance immune suppressive therapy after transplantation (steroids, tacrolimus, 
sirolimus and/or mycophenolate mofetil). Beyond doubt, pre-existing donor-specific 
allo-Abs are detrimental, while thyroid autoAbs (anti-thyroid peroxidase) at baseline 
are highly predictive of development of Graves’ disease after tapering of immune 
suppression following loss of islet allograft function [61-63]. Changes in titres or 
recurrence and spreading of islet autoAb reactivities are associated with chronic loss 
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of β-cell function in most studies, but are not necessarily predictive of the future fate 
of the islet allograft [29, 64, 65]. 
Robust immune signatures of success as well as failures have been defined following 
islet engraftment that may differ among immune suppressive regimes [66, 67]. 
Important lessons are emerging from immune monitoring that may help guiding the 
choice of immune suppressive therapies. For instance, HLA Class I mismatching may 
avoid acute recurrence of CD8+ T-cell autoreactivity, whereas sirolimus-containing 
immune suppressive regimens add allo-reactivity as a factor contributing to loss of β-
cell function. Furthermore, immune monitoring studies increased our understanding 
of the mode of action of therapeutics and identified potential causes of T1D 
recurrence or drug failure (e.g., homeostatic expansion of islet-reactive memory T 
cells following debulking induction therapies) [68]. Preliminary studies on the effect of 
tapering of immune suppression after islet transplantation suggest that immune 
correlates can be defined that help guiding the tapering process [69]. In terms of 
favorable immunological outcome, the development of a donor-specific IL-10 
response in a mixed lymphocyte reaction associated with remission, whereas a 
proliferative response to donor HLA associated with relapse and loss of islet allograft 
function [58].  
Collectively, the various immune studies underscore the importance of addressing 
immune memory, as most immunosuppressive drugs employed for islet 
transplantation are chosen for their capacity to prevent rejection rather than to 
intervene in immunologically primed conditions such as chronic autoimmunity. New 
intervention strategies that specifically address autoimmune memory are required to 
improve transplantation outcomes and it is conceivable that immune biomarkers may 
assist in identifying and validating such strategies.   
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7. Some unmet needs for T1D immune staging in immune therapeutic trials 
The large majority of T-cell-based immune staging studies have been performed to 
monitor modifications induced following immune therapy. One aspect that needs 
more emphasis is that of immune staging before intervention, to identify T-cell 
profiles associated with clinical responses and thus to help selecting which patients 
to treat. Specific autoAb specificities (e.g. anti-GAD in the Diamyd GAD trial) have 
already been used as selection criteria in several immune intervention trials. The 
rationale is to treat with a given Ag only those patients who show autoAb evidence 
that the administered Ag is a target of active autoimmunity, and thus that there are 
responses amenable to therapeutic deviation through Ag administration. Indeed, 
there is little rationale to intervene on GAD-specific immune responses without 
evidence that these responses are active in a given patient. It should be noted 
however that formal proof for this rationale is lacking, as this would require treating 
for example with GAD-alum both anti-GAD autoAb-positive and -negative patients to 
resolve whether autoAb-positive vaccinees achieve better outcomes. However, 
results from the oral arm of the DPT-1 trial suggest that this autoAb-based selection 
strategy may be of relevance. In this trial, at-risk relatives of T1D patients were 
treated with oral insulin or placebo. Although the overall protection was not 
significant, post-hoc analyses of patients with starting higher IAA titers showed some 
protection [70]. Trial enrollment based on pre-treatment T-cell profiles may also 
improve clinical outcome, as suggested by the results discussed above for the 
DiaPep277 trial [52].  
Another gap in knowledge concerns the possibility to follow modifications of Ag-
specific Tregs. Several types of Tregs have been identified, including both CD4+ and 
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CD8+ T cells producing large amounts of IL-10 and TGF-β. It appears that in non-
diabetic individuals, potentially pathogenic T cells are held in check by various Treg-
dependent mechanisms. T1D may develop due, at least in part, to a defect (either 
functional or numerical) in the Treg repertoire or resilience of islet-reactive T cells to 
be suppressed [71]. Due to side effects associated with long-term generalized 
immunosuppression, the induction and maintenance of long-lasting tolerance specific 
to islet Ags remains a major focus for T1D clinical trials. Hence, to monitor the 
efficacy of these trials, assays are urgently required that are able to measure not only 
the decline in pro-inflammatory effector T cells, but also the expansion of islet-
specific Tregs. The definition of the Ag specificity of Tregs is required to this end. Islet 
Ag-specific Tregs in non-diabetic individuals have been described that are capable of 
suppressing the proliferation of T cells recently activated by insulin [72]. These 
studies indicate that islet-specific Tregs exist and can be detected in peripheral 
blood. While this further supports the possibility that islet-specific tolerance may be 
restored therapeutically, it also poses additional challenges for detecting cellular islet 
autoimmunity, as Treg-mediated suppression may mask such autoimmunity and 
impair functional assays aimed at monitoring it. 
Contrary to other autoimmune diseases, direct bioptic access to damaged islets is 
not available for T1D. Islet imaging is thus being intensively investigated. Magnetic 
resonance imaging (MRI) has thus far provided the most promising results, as it may 
offer two key elements: quantification of the islet mass and infiltration by immune 
cells. Gaglia et al. applied a MRI strategy to patients by intravenously injecting 
magnetic ferrous nanoparticles [73]. These nanoparticles accumulate in inflamed 
tissues owing to heightened vascular permeability and, upon extravasation, uptake 
by infiltrating phagocytes recruited at this site. Increased signal accumulation was 
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thus observed in pancreata of T1D patients compared to healthy individuals 48 h 
after nanoparticle injection, although no comparison with non-autoimmune T2D 
patients was performed. This is a critical control as low-grade islet inflammation is 
also present in T2D [74]. While MRI has high spatial resolution but low sensitivity, 
positron emission tomography (PET) has poorer spatial resolution but higher 
sensitivity. Therefore, combined PET and MRI techniques, in combination with 
specific imaging probes, may offer comprehensive functional and anatomical imaging 
of islet β cells and their infiltrates [75], which may also help in solving the current 
uncertainty about the correlation between residual β-cell mass and insulin secretion. 
 
8. Present and future: immune biomarkers for therapeutic tailoring 
Immune surrogate endpoints should be systematically added to clinical and metabolic 
outcomes in order to comprehensively evaluate trial results. At present, this would 
allow: 
1) To understand therapeutic mechanisms behind clinical efficacy. 
2) To sort out the reasons for lack of clinical efficacy in many trials: is the intervention 
immunologically ineffective or is the immune effect insufficient to translate into clinical 
benefit? 
3) To define pre-treatment and post-treatment immune profiles associated with 
clinical benefits. 
Following wider implementation of these immune surrogate endpoints, the 
information gathered could allow: 
1) To further explore therapeutic strategies inducing the desired immune 
modifications, even in the absence of clinical benefit. Following appropriate 
modifications in formulation, regimens, association with other agents or targeted 
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patient population, such strategies may increase chances of achieving clinical 
efficacy. 
2) To perform trials of smaller size, using immune surrogate endpoints for which 
expected changes are wider than for metabolic and clinical endpoints.   
3) To perform trials of shorter duration, using early immune surrogate endpoints 
rather than late metabolic and clinical endpoints.  
4) To encourage trial implementation at an earlier stage of disease (i.e. for T1D 
prevention in at-risk subjects) once data about safety and immune efficacy is 
obtained in new-onset T1D patients, independent of clinical outcome; 
5) To improve enrollement strategies, based on pre-treatment immune profiles 
associated with clinical benefit; 
6) To tailor immune therapies for each subject, both in terms of therapeutic agent 
(based on pre-treatment staging) and of treatment dose and duration (based on 
immune monitoring during treatment); 
The challenge for the coming decade is to refine and harness this knowledge to 
design effective and safe intervention strategies, to construct monitoring algorithms 
for use in intervention studies and islet transplantation, and to achieve greater insight 
into triggers, accelerants and modulators of T-cell autoimmunity. 
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Figure legends 
Figure 1. Biomarkers of prediction, prevention, diagnosis and intervention in type 1 
diabetes.  
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